PureCycle Technologies just beat Q1 estimates — and the shorts are barely flinching.
The stock closed at $7.65 on Tuesday, up 8% on the week and 41% over the past month. Q1 EPS came in at -$0.21, beating the -$0.25 consensus estimate. Revenue of $4.1 million also topped the $3.8 million forecast. That's a meaningful beat for a company still in ramp mode — and the price action before results suggested some were already repositioning ahead of it. Yet the scale of short positioning means the squeeze narrative is far from finished.
The borrow market tells a story of unusually high conviction against the stock. Short interest is 28.5% of the free float — roughly 51.4 million shares — with cost to borrow running at 13% APR, nearly double where it was six weeks ago (7.1% at the start of April). Lending pool availability has tightened sharply through the month, with near-full occupation of available shares: borrowing activity is running at 93.7% of the full lending capacity, just off the 52-week peak of 100% recorded earlier in the year. Despite the 41% monthly price surge, short interest has actually grown on a one-month basis — up 7.4% — suggesting that rather than closing positions, bears have been adding into the rally. Days to cover from FINRA data is 13.2, meaning the short base would need nearly three weeks of full daily volume to unwind.
Options traders have shifted toward the cautious end of their recent range, though not dramatically so. The put/call ratio is 0.53, roughly 2.6 standard deviations above its 20-day average of 0.49. That's the highest it has been in the past year, approaching the 52-week PCR peak of 0.59. It's a modest-magnitude skew by broader market standards, but the z-score represents the sharpest defensive tilt seen on this name in the trailing twelve months. For a stock that rallied 41% in a month, call-heavy enthusiasm is notably absent.
The Street remains broadly constructive but has been reassessing targets in the wake of the company's difficult Q4. The most recent analyst move — Cantor Fitzgerald maintaining its Overweight rating while cutting to a $14 target after February's print — captures the bull case well: long-term technology thesis intact, near-term execution still uncertain. ORTEX's short score is 88.6 out of 100, placing PCT in the most highly scrutinised tier of the universe — a composite that reflects high short interest, tight availability, and elevated cost of borrow acting together. Factor scores tell a pre-profitability story throughout: negative earnings yield, negative P/E, and a net debt position of $375 million against annual revenues running at roughly $40 million. The bull thesis from analysts centres on gross margin improvement to 25-30% by FY26-27 and UPR resin sales scaling to 91 million pounds — targets that, if hit, would transform the financials entirely.
Institutional ownership is notable for its concentration. Sylebra Capital holds 18.9% of shares — a single long-only fund with a dominant stake. Abundance Wealth Counselors added more than 6.7 million shares in Q1 2026, lifting its position to nearly 5% of outstanding shares. BlackRock added 250,000 shares through April. That's a set of institutions building into a name that bears are simultaneously loading up on — a direct ownership tug-of-war that rarely stays quiet.
What to watch now is whether today's Q1 beat translates into any meaningful reduction in short interest at the next FINRA settlement read, and whether management commentary on the earnings call provides new detail on the FY26 resin-volume ramp that underpins every bull price target.
See the live data behind this article on ORTEX.
Open PCT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
